Holen Sie sich die Stockscreener-App
12.33
1.99%
0.24
Handel nachbörslich:
12.39
0.06
+0.49%
Schlusskurs vom Vortag:
$12.09
Offen:
$12.34
24-Stunden-Volumen:
590.54K
Relative Volume:
0.74
Marktkapitalisierung:
$914.17M
Einnahmen:
$97.36M
Nettoeinkommen (Verlust:
$-172.42M
KGV:
-5.3646
EPS:
-2.2984
Netto-Cashflow:
$-188.84M
1W Leistung:
+4.76%
1M Leistung:
-0.88%
6M Leistung:
-25.36%
1J Leistung:
+30.75%
1-Tages-Spanne:
$12.02
$12.53
1-Wochen-Bereich:
$11.20
$12.53
52-Wochen-Spanne:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.33 | 914.17M | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-29 | Hochstufung | Barclays | Underweight → Overweight |
| 2025-09-17 | Fortgesetzt | Barclays | Underweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2024-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution - Yahoo Finance
Xencor Inc Stock (US98401F1057): Analyst Views In Focus After Recent Collaboration Momentum - AD HOC NEWS
Understanding Momentum Shifts in (XNCR) - Stock Traders Daily
Xencor (XNCR) Slides 2% as Biotech Sentiment Weakens — Support TestedTRIN Signal - newsline.com
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial - MSN
Xencor Inc stock (US98401F1057): shares react to Monjuvi first-line lymphoma update and recent Q1 20 - AD HOC NEWS
XNCR Technical Analysis & Stock Price Forecast - Intellectia AI
XNCR Q1 2026 Earnings: Deep Loss Miss as Pipeline Biotech Faces Market SkepticismInterim Report - The Legal Advocate
XNCR Q1 2026 Earnings: Significant EPS Miss Amidst Clinical Development ProgressAnnual Report - newsline.com
XNCR Q1 2026 Earnings: Deeper-than-Expected Loss Highlights Persistent R&D InvestmentEarnings Revision Upgrade - newsline.com
Xencor Inc stock (US98401F1057): shares trade around recent lows as investors digest pipeline and va - AD HOC NEWS
Avoiding Lag: Real-Time Signals in (XNCR) Movement - Stock Traders Daily
XNCR Q1 2026 Earnings: Large EPS Miss Amid Pre-Revenue Status; Stock Gains SlightlyEarnings Acceleration Picks - newsline.com
Xencor Inc. (XNCR) Holds Ground Near $11.31: Key Levels in FocusComposite Profile - Newser
Jefferies Financial Group Inc. Purchases 620,440 Shares of Xencor, Inc. $XNCR - MarketBeat
Xencor, Inc. (XNCR) Competitors - Meyka
Xencor Inc. (XNCR) Holds Near Support as Biotech Sector Shows Mixed SignalsCrowd Entry Points - Newser
Xencor (XNCR) Q1 2026 Underperforms: Key Challenges AheadPro Level Trade Signals - Newser
Xencor’s SWOT analysis: biotech stock faces pipeline execution test - Investing.com
Xencor’s SWOT analysis: biotech stock faces pipeline execution test By Investing.com - Investing.com Canada
Xencor (XNCR) Q1 2026 Disappoints — EPS $-1.71 Below $-0.79 ViewsPopular Trader Picks - Newser
T-cell Engagers Market to Record US$ 58.04 billion by 2035., - openPR.com
Xencor Inc stock (US98401F1057): JPMorgan lifts target while investors eye Q1 2026 update - AD HOC NEWS
Xencor, Inc. $XNCR Shares Sold by UBS Group AG - MarketBeat
EcoR1 reports 2.9% Xencor stake (NASDAQ: XNCR) - Stock Titan
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR) - The Globe and Mail
Xencor stock (US98401F1057): Biotech focus on immunotherapy and protein engineering - AD HOC NEWS
Xencor (XNCR) Declines -2.50% Amid Market Weakness 2026-05-14Undervalued Stocks - Newser
TradingKey - TradingKey
Xencor stock (US98401F1057): Biotech innovator in antibody therapies - AD HOC NEWS
Xencor Is Maintained at Neutral by JP Morgan - Moomoo
TD Cowen Maintains Xencor(XNCR.US) With Buy Rating - Moomoo
J.P. Morgan Maintains Xencor(XNCR.US) With Hold Rating, Raises Target Price to $14 - Moomoo
Xencor (NASDAQ:XNCR) Price Target Raised to $14.00 at JPMorgan Chase & Co. - MarketBeat
These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts - simplywall.st
XNCR (Xencor) crushes Q4 estimates with 85% earnings surprise, revenue rises 13.7%, shares jump 4.5%.Open Signal Network - Newser
Xencor (NASDAQ:XNCR) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Xencor (XNCR) Receives a Buy from Wells Fargo - The Globe and Mail
These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat - Yahoo Finance
Xencor (NASDAQ:XNCR) Downgraded by Zacks Research to "Strong Sell" - MarketBeat
Xencor, Inc. (XNCR) Stock Analysis: Exploring A 132% Potential Upside In Biotech - DirectorsTalk Interviews
What Xencor (XNCR) is doing to earn customer loyalty (Falls Hard) 2026-05-08Double EMA - newsline.com
MSN Money - MSN
Number of shareholders of Xencor, Inc. – MUN:XE9 - TradingView
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Xencor (NASDAQ:XNCR) Releases Earnings Results, Misses Estimates By $1.06 EPS - MarketBeat
Earnings Flash (XNCR) Xencor, Inc. Reports Q1 Revenue $4.5M - marketscreener.com
Xencor: Q1 Earnings Snapshot - marketscreener.com
Xencor (NASDAQ: XNCR) posts deeper Q1 2026 loss amid royalty dispute and Zenas write-down - Stock Titan
Xencor, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Xencor (NASDAQ: XNCR) Q1 loss widens as revenue and royalties fall - Stock Titan
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.04%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):